• Completed

NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab

Updated: May 26


NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab


PET Imaging MM with 89Zr-DFO-daratumumab

The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.


Phase I/II study with the goal to assess the feasibility of using the anti-CD38 monoclonal antibody daratumumab, labeled with Zirconium-89 (89Zr ) through deferoxamine (DFO), known as 89Zr-DFO-daratumumab, for PET imaging of multiple myeloma.


ClinicalTrials.gov Identifier: NCT03665155


Official Title: First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

 

89Zr-DFO-daratumumab - National Cancer Institute

 

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging

Radiology; 2020 Jun

https://pubmed.ncbi.nlm.nih.gov/32255416/


- New York: Memorial Sloan-Kettering Cancer Center New York


Posts Archive